Frequency of LRRK2 mutations in early- and late-onset Parkinson disease
- PMID: 17050822
- DOI: 10.1212/01.wnl.0000244345.49809.36
Frequency of LRRK2 mutations in early- and late-onset Parkinson disease
Abstract
Objective: To evaluate the frequency of leucine-rich repeat kinase gene (LRRK2) mutations and single nucleotide polymorphisms (SNPs) in early-onset Parkinson disease (EOPD) and late-onset Parkinson disease (LOPD).
Methods: We genotyped five previously reported LRRK2 mutations (G2019S, L1114L, I1122V, R1441C, and Y1699C) and 17 coding SNPs for haplotype analysis in 504 cases with PD and 314 controls enrolled in the Genetic Epidemiology of PD Study. Cases and controls were recruited without knowledge of family history of PD and cases were oversampled in the < or =50 age at onset (AAO) category.
Results: The LRRK2 G2019S mutation was present in 28 cases with PD (5.6%) and two controls (0.6%) (chi(2) = 13.25; p < 0.01; odds ratio 9.18, 95% CI: 2.17 to 38.8). The mutations L1114L, I1122V, R1441C, and Y1699C were not identified. The frequency of the LRRK2 G2019S mutation was 4.9% in 245 cases with AAO < or =50 years vs 6.2% in 259 cases with AAO >50 (p = 0.56). All cases with PD with the G2019S mutation shared the same disease-associated haplotype. The frequency of the LRRK2 G2019S mutation was higher in the subset of 181 cases reporting four Jewish grandparents (9.9%) than in other cases (3.1%) (p < 0.01). Age-specific penetrance to age 80 was 24% and was similar in Jewish and non-Jewish cases.
Conclusions: The G2019S mutation is a risk factor in both early- and late-onset Parkinson disease and confirms the previous report of a greater frequency of the G2019S mutation in Jewish than in non-Jewish cases with Parkinson disease.
Similar articles
-
The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?Neurology. 2007 Oct 16;69(16):1595-602. doi: 10.1212/01.wnl.0000277637.33328.d8. Neurology. 2007. PMID: 17938369
-
Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry.Mov Disord. 2017 Oct;32(10):1432-1438. doi: 10.1002/mds.27059. Epub 2017 Jun 22. Mov Disord. 2017. PMID: 28639421 Free PMC article.
-
Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease.Neurology. 2007 Sep 18;69(12):1270-7. doi: 10.1212/01.wnl.0000276989.17578.02. Neurology. 2007. PMID: 17875915 Free PMC article.
-
The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.J Neural Transm (Vienna). 2009 Nov;116(11):1473-82. doi: 10.1007/s00702-009-0303-0. J Neural Transm (Vienna). 2009. PMID: 19756366 Review.
-
Clinical features of LRRK2 parkinsonism.Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S205-8. doi: 10.1016/S1353-8020(09)70815-6. Parkinsonism Relat Disord. 2009. PMID: 20082991 Review.
Cited by
-
Creation of an open-access, mutation-defined fibroblast resource for neurological disease research.PLoS One. 2012;7(8):e43099. doi: 10.1371/journal.pone.0043099. Epub 2012 Aug 27. PLoS One. 2012. PMID: 22952635 Free PMC article.
-
Environmental-genetic interactions in the pathogenesis of Parkinson's disease.Exp Neurobiol. 2012 Sep;21(3):123-8. doi: 10.5607/en.2012.21.3.123. Epub 2012 Sep 17. Exp Neurobiol. 2012. PMID: 23055790 Free PMC article.
-
Sex differences in movement disorders.Nat Rev Neurol. 2020 Feb;16(2):84-96. doi: 10.1038/s41582-019-0294-x. Epub 2020 Jan 3. Nat Rev Neurol. 2020. PMID: 31900464 Review.
-
Cognitive Impairment in Genetic Parkinson's Disease.Parkinsons Dis. 2021 Dec 30;2021:8610285. doi: 10.1155/2021/8610285. eCollection 2021. Parkinsons Dis. 2021. PMID: 35003622 Free PMC article. Review.
-
A Comprehensive Analysis of Population Differences in LRRK2 Variant Distribution in Parkinson's Disease.Front Aging Neurosci. 2019 Jan 30;11:13. doi: 10.3389/fnagi.2019.00013. eCollection 2019. Front Aging Neurosci. 2019. PMID: 30760999 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical